Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932801 · ClinicalTrials.gov registry record · Phase 2
Harm Reduction With Pharmacotherapy (HaRP)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
NCT01932801: Completed Phase 2 study, sponsored by University of Washington.
NCT01932801 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 308 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (132% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01932801, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
Study Summary
The goal of this study is to test the efficacy of extended-release naltrexone and harm reduction counseling in reducing alcohol-related harm among homeless people with alcohol dependence.
Primary Outcome
Using the Alcohol Quantity and Use Assessment, we will collect data on peak alcohol quantity.
Interventions
- OTHER Placebo
- DRUG XR-NTX
- BEHAVIORAL HRC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 2 |
What the finished NCT01932801 record still lists
NCT01932801 is an interventional study that assigns participants to a tested intervention. The registered 308 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (132% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01932801 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01932801 about?
NCT01932801 is a clinical study titled "Harm Reduction With Pharmacotherapy (HaRP)". The goal of this study is to test the efficacy of extended-release naltrexone and harm reduction counseling in reducing alcohol-related harm among homeless people with alcohol dependence.
What is the current status of trial NCT01932801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2013-08-01. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT01932801?
The interventions under investigation include: Placebo (OTHER), XR-NTX (DRUG), HRC (BEHAVIORAL).
Who is sponsoring clinical trial NCT01932801?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01932801's enrollment target sits among peer trials
308 163rd of 2000 higher than 1,836 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- NCT06233942 · 308 participants · Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI